Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Azimer is an oral macrolide antibiotic containing azithromycin, marketed by Merlion Lifescience. It exerts its antibacterial effect by binding to the 50S subunit of the bacterial ribosome, which inhibits RNA-dependent protein synthesis and prevents bacterial growth. Azimer is indicated for the treatment of various bacterial infections, including respiratory tract infections (such as pneumonia, bronchitis, and sinusitis), skin and soft tissue infections, sexually transmitted diseases (including chlamydia and gonorrhea), and typhoid fever. As a generic formulation, it is typically provided in tablet form for convenient oral administration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Azimer.